Frequent evaluation of renal function and appropriate dose adjustment or suspension of DOACs are crucial in patients developing acute kidney injury to prevent severe bleeding complications.
Renal decline on rivaroxaban may raise intracranial bleed risk; single case leaves open validated monitoring and adjustment protocols.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kataoka et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: